Provided by Tiger Trade Technology Pte. Ltd.

Penumbra

335.57
+0.58250.17%
Volume:34.58K
Turnover:11.59M
Market Cap:13.14B
PE:74.24
High:337.00
Open:337.00
Low:334.90
Close:334.99
52wk High:362.41
52wk Low:221.26
Shares:39.16M
Float Shares:37.83M
Volume Ratio:0.30
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):4.52
EPS(LYR):4.52
ROE:13.78%
ROA:7.04%
PB:9.21
PE(LYR):74.24

Loading ...

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio?

Benzinga_recent_news
·
Nov 09, 2025

Penumbra Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Nov 07, 2025

Penumbra price target raised to $286 from $285 at Evercore ISI

TIPRANKS
·
Nov 07, 2025

Penumbra Up Nearly 20%, on Pace for Largest Percent Increase Since November 2015 -- Data Talk

Dow Jones
·
Nov 07, 2025

Truist Raises Price Target on Penumbra to $312 From $300, Keeps Buy Rating

MT Newswires Live
·
Nov 06, 2025

Stock Track | Penumbra Soars 19.36% in Pre-market Following Multiple Analyst Upgrades and Strong Q3 Performance

Stock Track
·
Nov 06, 2025

Penumbra Inc : Leerink Partners Raises Target Price to $332 From $327

THOMSON REUTERS
·
Nov 06, 2025

Buy Rating for Penumbra: Strong Q3 Performance and Future Growth Catalysts

TIPRANKS
·
Nov 06, 2025

Penumbra Q3 Non-GAAP Earnings, Revenue Rise; Shares Gain After Hours

MT Newswires Live
·
Nov 06, 2025

GUIDANCE: (PEN) Penumbra Expects Full Year 2025 Revenue Range $1.375 Billion - $1.38 Billion, vs. FactSet Est of $1.37 Billion

MT Newswires Live
·
Nov 06, 2025

Stock Track | Penumbra Soars 7% After Hours on Q3 Revenue Beat, Raised Guidance

Stock Track
·
Nov 06, 2025

Medical equipment maker Penumbra beats Q3 revenue estimates, raises revenue forecast

Reuters
·
Nov 06, 2025

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

Benzinga
·
Nov 06, 2025

Buy Rating on Penumbra: Capitalizing on Positive STORM-PE Trial Results and Market Misunderstanding

TIPRANKS
·
Nov 04, 2025

Penumbra Reports Positive Data for Pulmonary Embolism Treatment

Dow Jones
·
Nov 04, 2025

Penumbra's STORM-PE Trial Shows CAVT with Anticoagulation Significantly Improves Outcomes in Pulmonary Embolism

Reuters
·
Nov 04, 2025

Penumbra (PEN) Receives a Buy from RBC Capital

TIPRANKS
·
Oct 29, 2025

William Blair healthcare analysts hold analyst/industry conference call

TIPRANKS
·
Oct 28, 2025

Penumbra Inc.’s STRIKE-PE Study: A Game Changer for Pulmonary Embolism Treatment?

TIPRANKS
·
Oct 28, 2025

Truist Financial Sticks to Its Buy Rating for Penumbra (PEN)

TIPRANKS
·
Oct 27, 2025